Celldex Therapeutics - Recruiting 18 years or older. - An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma.
Rindopepimut (CDX-110) with GM-CSF; Temozolomide; KLH
Celgene Corporation - Recruiting 18 years or older. - A Phase 1a/b, Multicenter, Open Label, Dose-Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Dual DNA-PK and TOR Kinase Inhibitor, CC-115, Administered Orally to Subjects With Advanced Solid Tumors, and Hematologic Malignancies..
Karyopharm Therapeutics, Inc - Recruiting 18 years or older. - A Phase II, Two-tier Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Patients With Recurrent Glioblastoma After Failure of Radiation Therapy and Temozolomide.
National Cancer Institute (NCI) - Recruiting N/A to 21 years. - A Phase I/II Study of ABT-888, an Oral Poly(ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, Followed by ABT-888 and Temozolomide, in Children With Newly Diagnosed Diffuse Pontine Gliomas (DIPG).
National Cancer Institute (NCI) - Recruiting 37 Months to 21 years. - A Phase 1 Study of MK-1775 Concurrent With Local Radiation Therapy for the Treatment of Newly Diagnosed Children With Diffuse Intrinsic Pontine Gliomas.
Genentech - Recruiting 18 years or older. - An Open-label, Phase I, Dose-escalation Study Evaluating the Safety and Tolerability of GDC-0084 Administered to Patients With Progressive or Recurrent High-grade Glioma.
CytRx - Recruiting 18 years or older. - An Open-Label Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of Aldoxorubicin in Subjects With Unresectable Glioblastoma Whose Tumors Have Progressed Following Prior Treatment With Surgery, Radiation and Temozolomide.
Bristol-Myers Squibb - Recruiting 18 years or older. - A Randomized Phase IIb, Open Label Study of Nivolumab or Nivolumab in Combination With Ipilimumab Versus Bevacizumab in Adult Subjects With Recurrent Glioblastoma (GBM).
National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 66 years. - A Phase I/II Study of the Safety and Feasibility of Administering T Cells Expressing Anti-EGFRvIII Chimeric Antigen Receptor to Patients With Malignant Gliomas Expressing EGFRvIII.
Anti-EGFRvIII CAR (PG13-139-CD8-CD28BBZ (F10) transduced PBL; Aldesleukin; Fludarabine; Cyclophosphamide
GenSpera, Inc. - Recruiting 18 years or older. - An Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy, Safety and CNS Exposure of G-202 in Patients With Recurrent or Progressive Glioblastoma.
Roswell Park Cancer Institute - Recruiting 18 years or older. - A Phase I Clinical Trial of mTOR Inhibition With Rapamycin for Enhancing Intranodal Dendritic Cell Vaccine Induced Anti-tumor Immunity in Patients With NY-ESO-1 Expressing Solid Tumors.
DEC-205-NY-ESO-1 fusion protein vaccine; sirolimus; laboratory biomarker analysis
Duke University - Recruiting 18 years or older. - REGULATory T-Cell Inhibition With Basiliximab (Simulectr) During Recovery From Therapeutic Temozolomide-induced Lymphopenia During Antitumor Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed Glioblastoma Multiforme.
Technische Universitt Dresden - Recruiting 18 years or older. - Observational Study of Impact of [11C]-Methionine PET/MRI as a Tool for Individual Tailoring Postoperative Radiochemotherapy for Patients With Glioblastoma Multiforme.
CytoVac A/S - Recruiting 18 years or older. - An Open-labelled, Randomized Phase II Multicentre Study to Investigate Efficacy of Autologous Lymphoid Effector Cells Specific Against Tumour-Cells (ALECSAT) in Patients With Glioblastoma Multiforme Measured as Progression Free Survival Compared to Avastin/Irinotecan.
Washington University School of Medicine - Recruiting 18 years or older. - A Pilot Study of Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Doxorubicin in the Treatment of Recurrent Glioblastoma Multiforme.
Roswell Park Cancer Institute - Recruiting 18 years or older. - Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients With Survivin-Positive Malignant Gliomas.
Institut Cancerologie de l'Ouest - Recruiting 18 years to 70 years. - Phase I Study of Escalated Pharmacologic Dose, of Oral Folinic Acid in Combination With Temozolomide, According to Stupp R. Regimen, in Patients With Operated Grade-IV Astocytoma and a Non-methylated Gene Status of MGMT..
Temozolomide; folinic acid at pharmacological dose is the escalated drug; High voltage radiation therapy (linear accelerator)
Amgen - Recruiting 18 years or older. - A Phase 1 First-in-Human Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 595 in Subjects With Recurrent Malignant Glioma Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFRvIII).
Cortice Biosciences, Inc. - Recruiting 18 years or older. - Phase 2 Dose-Escalation Study of TPI 287 in Combination With Bevacizumab in Adults With Recurrent or Progressive Glioblastoma Following Bevacizumab Alone.
St. Joseph's Hospital and Medical Center, Phoenix - Recruiting 18 years to 80 years. - Phase I/II Prospective Trial for Newly Diagnosed GBM, With Upfront Gross or Subtotal Resection, Followed by Ketogenic Diet With Radiotherapy and Concurrent Temodar(R) Chemotherapy Followed by Adjuvant Temodar(R) Chemotherapy..
National Cancer Institute (NCI) - Recruiting 18 years or older. - Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma.
GW Pharmaceuticals Ltd. - Recruiting 18 years or older. - A Two Part Study to Assess the Tolerability, Safety and Pharmacodynamics of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma.
Massachusetts General Hospital - Recruiting 18 years or older. - A Study to Evaluate Vascular Normalization in Patients With Recurrent Glioblastoma Treated With Bevacizumab Using [11C]Temozolomide PET and Vascular MRI.
Beth Israel Medical Center - Recruiting 18 years to 70 years. - STRONG Trial - Stem Cell Radiotherapy (ScRT) and Temozolomide for Newly Diagnosed High-grade Glioma (HGG): A Prospective, Phase I/II Trial.
Tocagen Inc. - Recruiting 18 years to 80 years. - A P1 Ascending Dose Trial of the Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered Intravenously Prior to, and Intracranially at the Time of, Subsequent Resection for Recurrent HGG & Followed by Treatment With Extended-Release 5-FC.
National Cancer Institute (NCI) - Recruiting 18 years or older. - Phase I/Comparative Randomized Phase II Trial of TRC105 Plus Bevacizumab Versus Bevacizumab in Bevacizumab-Nave Patients With Recurrent Glioblastoma Multiforme.
anti-endoglin monoclonal antibody TRC105; bevacizumab; laboratory biomarker analysis; pharmacological study
Pediatric Brain Tumor Consortium - Recruiting 16 years to 21 years. - A Phase I Study of Intratumoral/Peritumoral Herpes Simplex Virus-1 Mutant HSV1716 in Patients With Refractory or Recurrent High Grade Gliomas (HGG).
Hoffmann-La Roche - Recruiting 18 years or older. - A Double-blind, Placebo-controlled, Randomized, Phase IIIb Trial Evaluating the Efficacy and Safety of Standard of Care (SOC) +/- Continuous Bevacizumab Treatment Following Progression of Disease (PD) in Patients With Glioblastoma (GBM) After First (1st)-Line Treatment With Radiotherapy, Temozolomide and Bevacizumab.
SCRI Development Innovations, LLC - Recruiting 18 years or older. - Phase I/II Study of the Combination of BKM120 and Bevacizumab in Patients With Refractory Solid Tumors (Phase I) and Relapsed/Refractory Glioblastoma Multiforme (Phase II).
M.D. Anderson Cancer Center - Recruiting 18 years or older. - A Phase I lead-in to a 2x2x2 Factorial Trial of Dose Dense Temozolomide, Memantine, Mefloquine, and Metformin As Post-Radiation Adjuvant Therapy of Glioblastoma Multiforme.
AbbVie - Recruiting 18 years or older. - A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-414 in Combination With Radiation Plus Temozolomide or Temozolomide Alone for Subjects With Glioblastoma Multiforme.
Cancer Research UK - Recruiting 18 years to 70 years. - A Cancer Research UK Phase I Trial of Olaparib (AZD2281), an Oral PARP Inhibitor, in Combination With Extended Low-Dose Oral Temozolomide in Patients With Relapsed Glioblastoma.
olaparib; temozolomide; gene expression analysis; protein expression analysis; laboratory biomarker analysis; pharmacological study; diffusion-weighted magnetic resonance imaging; dynamic contrast-enhanced magnetic resonance imaging; therapeutic conventional surgery
Northwestern University - Recruiting 18 years or older. - A Phase II Study of the Efficacy of Hypofractionated Radiation Therapy With Bevacizumab and Temozolomide Followed by Maintenance Temozolomide and Bevacizumab for Recurrent High-Grade Gliomas.
Grupo Espa¤ol de Investigaci¢n en Neurooncolog¡a - Recruiting 18 years or older. - A Prospective Multicenter, Open Label, Phase II Pilot Clinical Trial to Evaluate Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation.
Actelion - Recruiting 18 years or older. - A Phase 1/1b, Open-label Study in Patients With Recurrent Glioblastoma to Assess the Safety and Tolerability of Macitentan in Combination With Dose-dense Temozolomide.
Phase 1 Dose Escalation; Phase 1b; Ancillary Study
University Hospital, Geneva - Recruiting 18 years or older. - Phase I/II Study of Intradermal IMA950 Peptide-based Vaccine Adjuvanted With Intra Muscular Poly-ICLC in Combination With Temozolomide in Newly Diagnosed HLA-A2 Glioblastoma Patients.
IMA 950 multipeptide based vaccine; Poly ICLC; Temozolomide; radiotherapy; Immunomonitoring
Medical University of South Carolina - Recruiting 18 years to 80 years. - Imaging Biomarkers of Tissue Microstructure and Vasculature as Predictors of Glioblastoma Multiforme Response to Treatment With Bevacizumab for Progressive Disease.
Novartis - Recruiting 18 years or older. - A Phase I, Two-stage, Multi-center, Open Label, Dose-escalation Study of BKM120 in Combination With Adjuvant Temozolomide and With Concomitant Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma.
Johann Wolfgang Goethe University Hospitals - Recruiting 18 years or older. - Calorie-restricted, Ketogenic Diet and Transient Fasting vs. Standard Nutrition During Reirradiation for Patients With Recurrent Glioblastoma: the ERGO2 Study.
calorie-restricted ketogenic diet and transient fasting; standard nutrition
Eisai Inc. - Recruiting N/A or older. - An Open-Label, Multicenter Phase 1b/2 Study of E7050 in Combination With E7080 in Subjects With Advanced Solid Tumors (Dose Escalation) and in Subjects With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2).
E7050 plus E7080; E7080 plus E7050; E7050 plus E7080 or E7080 alone plus E7050 add-on therapy; E7050
University Hospital Heidelberg - Recruiting 18 years or older. - Randomized Phase II Study Evaluating a Carbon Ion Boost Applied After Combined Radiochemotherapy With Temozolomide Versus a Proton Boost After Radiochemotherapy With Temozolomide in Patients With Primary Glioblastoma.
National Cancer Institute (NCI) - Recruiting 18 years or older. - Phase I/Randomized Phase II Trial of Either Dasatinib or Placebo Combined With Standard Chemo-Radiotherapy for Newly Diagnosed Glioblastoma Multiforme (GBM).
Weill Medical College of Cornell University - Recruiting 18 years or older. - Phase I Trial of Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab) For Treatment of Relapsed/Refractory Glioblastoma Multiforme and Anaplastic Astrocytoma.
Super-Selective Intraarterial Intracranial Infusion of BEVACIZUMAB
Weill Medical College of Cornell University - Recruiting 18 years or older. - Phase I/II Trial Of Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory Glioblastoma Multiforme And Anaplastic Astrocytoma.
Northern Sydney and Central Coast Area Health Service - Recruiting 18 years or older. - Phase 11 Study of Cilengitide in Combination With Concurrent Chemotherapy and Radiotherapy Followed by Protracted Daily Low Dose Temozolomide and Low Dose Procarbazine D1 - 20 in Newly Diagnosed Glioblastoma Without Methylation of the MGMT Promoter Gene.